Objective. To summarize the state of knowledge with regard to the economic impact of rheumatoid arthritis (RA) and to highlight any weaknesses in the work conducted to date, so as to inform future RA cost-of-illness studies.
The economic burden of rheumatoid arthritis (RA) is Indirect costs are costs for which resources are lost, but no direct payment is actually made. They can be thought to be substantial for both people with RA and health services. As a whole, musculoskeletal disorders classified into two groups: morbidity costs which are mainly productivity losses borne by the individual, their impose a considerable burden upon society in terms of morbidity, long-term disability and cost, but their impact family, society and employer due to illness, and mortality costs which are the present value of lost production due in terms of mortality is low compared to other disease groups [1] .
to premature death caused by illness. The third category of costs are referred to as psychoThe quantification of all costs associated with a social or intangible costs. These costs represent the particular disease(s), such as RA, can be used as a deterioration in the quality of life of patients, as well as proxy for the medical and economic burden it places their families and friends [6 ] . For example, people with upon society or a target audience such as the patient, RA may suffer from disability, pain, reduced self-esteem the health service or society as a whole, depending on and feelings of well-being. These costs are extremely the viewpoint adopted [2] . Such studies are known as difficult to quantify and, therefore, are often omitted cost-of-illness (COI ) studies [3] [4] [5] and provide informafrom economic studies. tive data to emphasize the scale and nature of a disease This paper reports the results of a systematic review as a health problem, and raise the profile of people with of published COI studies of RA. The objective of COI that disease as a patient group. studies is not to inform choices about which treatment The methodology outlined by Rice [5] considered or therapy is the most cost-effective option for people COI valuations to consist of three cost components:
with RA, but to assist the decision-making process at direct costs, indirect costs and psychosocial costs. Direct policy and planning levels by identifying where the costs are defined as those costs for which actual paymajor burden of cost might lie in the treatment and care ments are made. They include medical costs such as of these people. treatment costs, hospital costs and medication, as well
The objectives of this paper are 2-fold: (i) to summaras personal costs such as transport costs to the health ize the state of knowledge with regard to the economic provider and specialist aids.
impact of RA and (ii) to highlight any weaknesses in the work conducted to date, so as to inform future RA COI studies.
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The first key element of COI studies, like all economic Methods studies, is the need to specify a viewpoint for the analysis Four computerized literature databases [Medline since a commodity may be a cost from, say, the patient's 1966-1997; BIDS-ISI 1981-1997 (both science and point of view but not from, say, that of the health social science citation indexes); BIDS-EMBASE services [7] . It is also important for the study population 1950-1997 ( Excerpta Medica)] were searched in the title, to be well defined in terms of sociodemographic characabstract and key word fields using the following:
teristics and disease severity to assist the decision-making process and to allow comparisons to be performed $ Rheumatoid arthritis across studies. The third and fourth key elements state $ Arthritis the need for all COI studies to include the most import-$ Economics ant and relevant costs for the viewpoint adopted, $ Costs although it may not be possible for studies to measure $ Cost analysis and include all the costs incurred. Fifthly, when COI $ Cost-of-illness studies are conducted over >1 yr, costs should be $ Burden-of-illness discounted to reflect the fact that costs in the future are Titles and abstracts (where available) of the publicavalued less highly than costs in the present [7] . The tions identified were then used to assess a paper's sixth key element states that the difference in costs potential relevance to this systematic review. The incluincurred by the study population and a disease-free sion and exclusion criteria used for this are outlined in population (i.e. incremental costs) should be calculated, Table 1 . At this stage, full transcripts of all the papers where possible, in addition to the main analysis to avoid deemed potentially relevant were obtained and their the assumption that without the disease of interest a reference lists checked for any papers not identified by person would incur no COI. Finally, it is important that the computerized search. Authors of conference all COI studies, like all economic studies, apply sensitivabstracts identified by the literature search were conity analysis to their study results to address the uncertacted for more detailed information on their study tainty, imprecision or methodological controversy findings.
present in most, if not all, studies [7] . Several recent efforts have been undertaken to define Throughout this report, all costs have been converted the necessary elements of economic evaluations [7] [8] [9] ; into 1996 US dollars using the consumer price index for however, no formal guidelines for COI studies have medical and non-medical resources [10] . Costs have also been established. Therefore, from the health economics been converted into UK sterling using the average literature, seven key elements of COI studies were comexchange rate for the appropriate years and are prepiled for use in this review. These key elements are sented in parentheses throughout the text. Where costs presented in Table 2 and each one briefly discussed have been converted into either US dollars or UK below.
sterling from other currencies, these costs should only be used as a guide because official exchange rates do not adequately reflect the comparative purchasing power Table 1 perspective $ Personal papers/case studies and were therefore included in the critical review process.
$ No costs quoted in the result section
Eleven of the COI study papers identified for review $ Conference abstracts or came from the USA and one each from Canada, Sweden, review papers
The Netherlands and the UK.
Cost-of-illness criteria
T 2. Seven key elements of cost-of-illness studies [8] [9] [10] [33] [ + ] [12] [ + ] [13] [
Notation based on Rothfuss et al. [8] : +, present; [ + ], partly fulfilled; 0, absent.
Discounting was only applicable to one study [11] as with the mean age ranging from 48 to 63 yr and the mean duration of disease from 0 to 21 yr. The mean all the others estimated costs over a 1 yr period. Three studies [12] [13] [14] estimated attributable costs and only level of functional disability, measured by the Health Assessment Questionnaire (HAQ), ranged from 0.96 to two studies [11, 15] used sensitivity analysis.
1.53 where stated. [ The HAQ is scored on a scale from Study design 0 to 3, where 0 = 'without difficulty', 1 = 'with some difficulty', 1 = 'with much difficulty' and 3 = 'unable to Two-thirds of all the studies identified selected their study cohort from a clinical setting rather than a comperform'.] munity setting. Only two studies [12, 13] 
adopted a
Costs of RA case-control study design to enable the differences in costs incurred by RA patients and non-RA patients The costs calculated by the different studies varied dramatically for all of the cost categories. Overall, the (incremental/attributable costs) to be calculated, rather than limiting themselves to the total costs incurred by mean annual direct costs associated with RA (excluding Stone [11] lifetime costs) were calculated to be US$5720 RA patients only (absolute total costs). By calculating the incremental costs, the assumption that an individual (.. = US$2933), with the highest costs being recorded by Meenan et al. [17] for the study population with the will incur no COI in the absence of RA is avoided.
A prevalence-based [16 ] study design, which involved youngest mean age (48 yr), one of the shortest disease durations (9.8 yr) and the greatest disease severity (i.e. the estimation of the total cost of RA in a given time period (usually 1 yr), was adopted by all studies, except all stage III RA patients) ( Table 5 ). Stone [11] estimated lifetime direct costs of RA to equal US$15 504 one. Stone [11] used an incidence-based [16 ] study design to estimate the lifetime costs of RA.
( UK£9690). The mean costs for out-patient visits and in-patient stays (excluding Stone [11] lifetime costs) A primary data collection process (questionnaires, interviews, diaries) was adopted by approximately twowere US$1855 (.. = US$921) and US$4944 (.. = US$7041), respectively. The percentage of RA thirds of the studies identified. The remainder used a secondary data collection process (national or communsufferers hospitalized in the cohorts studied ranged from 12% [14] to 26% [17] . For all studies, except two [18, ity databases, clinical opinion).
The majority of studies calculated the direct costs 19], in-patient costs were found to be the largest component of total annual medical costs associated with RA. associated with RA; however, many limited themselves to the medical costs (e.g. in-patient and out-patient Where indirect costs were considered, it was usually as the number of days absent from work per annum costs), excluding non-medical costs (e.g. transport, aids and home modifications). Six studies measured indirect due to RA; these ranged from 2.7 days/year [20] to 30 days/year [19] per patient in employment ( Table 4) . morbidity costs in terms of the income lost as a result of absence from work due to a person's RA and only
The mean annual indirect cost associated with RA (excluding Stone [11] lifetime costs) was calculated to Stone [11] estimated the mortality costs associated with RA.
be US$5822 (.. = US$8416). Stone [11] estimated the lifetime indirect costs to be US$37 501 ( UK£23 438) Study populations ( Table 5) .
Where incremental costs were calculated, direct med- Table 4 displays the patient characteristics of the different studies considered by this review. The percentage of ical costs of RA patients were estimated at US$7274 ( UK£4546) compared to US$1917 ( UK£1198) for nonfemales in each study cohort ranged from 68 to 83% arthritic people [12] , and indirect costs US$1874 Sensitivity analysis ( UK£1171) compared to US$849 ( UK£531) [13] .
Stone [11] found lifetime costs to range from US$38 834 Despite common opinion that indirect costs far exceed to US$90 948, depending upon the discount rate, incidirect costs [21] [22] [23] , the findings of this review were less dence and cost figures used. Clarke et al.
[15] found decisive ( Table 4) . Two of the four studies that estimated physician costs to increase between 1.0 and 6.4% when both direct and indirect costs reported direct costs to be physician reimbursement was modified, laboratory and the largest contributor of total cost (62-74%) [15, 24] , radiology costs to increase between 288 and 333% when and two studies [11, 17] reported indirect costs to be laboratory tests were varied, and indirect costs to increase between 1.4 and 17% when the number of approximately twice direct costs. disabled days was modified to include all institutionaltypes of costs incorporated into the different cost categories (i.e. direct and indirect) and how they were ized days.
calculated. For example, direct costs may include medical and/or non-medical costs, and medical costs may Discussion include primary and/or secondary health care, and secState of knowledge with regard to the economic impact ondary health care costs may include in-patients and/or of RA out-patients, and out-patient costs may include physician visits, medication and/or diagnostic tests, and so The economic impact of RA in terms of cost was on. The same is true for indirect costs that may or may reported to be substantial by all of the studies reviewed.
not include the imputed income loss of those people Overall, the mean annual direct and indirect costs per with RA outside the workforce, such as homemakers person with RA were found to be US$5720 ( UK£3575) and retirees. and US$5822 ( UK£3638), respectively, i.e. approxiFinally, the characteristics of the study population mately equal.
(age, sex, severity of disease, duration of disease), at From the individual study results reported in Table 5, recruitment to the study, may also have an effect on the it is apparent that vast cost discrepancies exist across cost estimates calculated by the different studies and studies (see below). Despite a thorough investigation of should, therefore, be stated clearly in the study publicathe data, this variation in cost estimates could not be tion. In the majority of papers reviewed above, study explained by the sociodemographic or clinical differences participants were recruited from a clinic or hospital that existed across study populations.
setting, which benefit from a relatively homogeneous By calculating the mean cost as the main statistic, it patient sample in terms of diagnosis, severity of disease is likely that the studies published to date have overand demographic characteristics [29] , but may prove estimated the annual per person costs of RA owing to less generalizable to the overall disease population by the positively skewed distribution associated with cost overrepresentation of the more severe RA patients. In data [25] . By comparing the median annual direct costs contrast, national or community-based populations can per person, in the three studies where available, agreeprovide a more reliable estimate about the range of ment is much improved and costs were found to range impacts of RA, in terms of restriction on activities and from US$1011 ( UK£631) [15] to US$1060 ( UK£663) medical care utilization. Where available, summary [26 ] . The mean annual direct costs for these three studies statistics on the characteristics of the different study ranged from US$2635 ( UK£1647) to US$7691 populations were extracted ( Table 4) , but no obvious ( UK£4807).
associations between these characteristics and the cost Overall, in-patient costs were found to represent the estimates achieved were apparent. largest proportion of direct costs, making less than a As all cost estimation contains some degree of uncerquarter of the RA patient population responsible for at tainty, imprecision or methodological controversy, it is least 43% [18] and up to 75% [17] of annual medical important for all studies to test the sensitivity of their costs associated with RA (excluding Liang et al. [19] results by reworking their analysis applying a series of cost estimates for both osteoarthritis and RA). different assumptions and/or estimates [7] . Only two Methodological problems studies [11, 15] out of the 14 reviewed in this paper performed sensitivity analysis. The discrepancies in the annual per person costs of RA across studies can be attributed to a number of methodo-
The generalizability of the cost of RA estimates to the wider population is difficult due to the communitylogical problems. The first, as mentioned above, is the use of the arithmetic mean to describe the data. Owing specific nature of many of the studies. For instance, the COI estimates presented above are not easily generalizto the positively skewed distribution of the cost data in many, if not all, of the studies reviewed above, the able across countries due to variations between health care systems. Most of the studies conducted to date median (together with the interquartile range) would have provided a better description of the distribution of have provided cost estimates specific to the US population and health care system. It is important, therefore, the cost data and a more informative measure of the average per person cost [27] . However, the mean and for more studies to be conducted to highlight the magnitude of the impact of the RA on the patient, society confidence interval are useful summary statistics to the policy maker, who may be interested in the total cost and the health care service in other countries, and also to assist the decision-making process in these countries of a particular disease for a cohort of patients as a whole [28] .
concerning the treatment and care of RA patients. Discrepancies in the cost of RA can also be attributed
Guidelines for future cost-of-illness studies to the absence of well-defined guidelines for COI studies, making comparisons across studies extremely difficult.
It is important that future studies designed to estimate the economic impact of RA: (i) report direct and indirect This is particularly true where authors have provided insufficient data about the unit costs and data sources costs separately as well as in aggregate [30] ; (ii) identify the different components of direct costs to help decision used, and makes it difficult for the reviewer to judge the reliability and validity of the cost estimates quoted. makers identify the budgets on which the major economic burden falls [30] ; (iii) clearly state the data Thirdly, studies need to be more explicit about the
